VERUVeru Inc.
The schedule
- Thu15Oct
High probability of equity financing given ongoing quarterly cash burn and upcoming critical trial readouts.
- Mon25Jan
Critical interim data readout evaluating enobosarm's efficacy in preserving muscle mass when combined with a GLP-1.
- Mon1Feb
Potential corporate updates on strategic partnerships contingent on the Phase 2b interim results.
- Tue9Feb
Q3 earnings emphasizing cash preservation and final preparations for the Q1 2027 interim analysis.
- Mon10May
Year-end financial results focusing on management's roadmap post-interim clinical analysis.
- Wed12May
Q1 earnings providing updates on remaining pipeline asset viability and cash runway.
Past
- Tue11Aug
Actual outcome: Bear · $2.63 at outcome
Veru reported in-line EPS of -$0.13 and confirmed that its Phase 2b PLATEAU clinical trial evaluating the enobosarm and semaglutide combination was fully enrolled. Despite achieving this enrollment milestone, the absence of new efficacy data or additional upside catalysts failed to drive momentum, resulting in a 5.7% decline in the stock.
Quarterly earnings focusing on cash runway and enrollment progress for the Phase 2b PLATEAU trial.
- Mon27Jul
Actual outcome: Bull · $2.33 at outcome
Veru announced it exceeded full enrollment targets for its Phase 2b PLATEAU clinical trial evaluating the enobosarm and semaglutide combination, keeping its interim analysis on track for Q1 2027. The stock surged well past the bull target, further fueled by a subsequent Notice of Allowance for a key U.S. patent covering this combination therapy, which significantly strengthened the company's intellectual property protection in the weight loss space.
Updates on the clinical pipeline, particularly interactions with the FDA regarding the enobosarm program.
- Wed13May
Actual outcome: Bull · $2.95 at outcome
Veru reported in-line EPS of -$0.26 for its fiscal second quarter and provided a reassuring pipeline update. The company confirmed that its Phase 2b PLATEAU clinical study evaluating enobosarm plus semaglutide is actively enrolling and remains on track for an interim analysis in the first quarter of 2027. Meeting earnings expectations while maintaining the clinical timeline for its key cardiometabolic asset drove the stock's 30.5% rally past the bull target.
Q1 2026 earnings around 2026-05-15 will focus on Veru Inc.'s operating loss trajectory, any residual legacy revenue, and, most critically, whether cash at the end of March supports at least 4–5 quarters of runway. At a base price of $2.44, a clean update with controlled quarterly burn and credible cost discipline could move the stock toward $2.80, while a larger-than-expected loss or vague commentary on financing would likely push shares down toward $2.80 by the 2026-06-21 outcome date.
